Ottawa, ON / ACCESSWIRE / March 31, 2014 / Avivagen Inc. (TSXV:
VIV), a wellness company developing and delivering products that
support and enhance the health and quality of life for animals and
the people who care for them, announces an agreement with Chonbuk
National University of the Republic of Korea (South Korea) to
conduct a trial of OxC-beta for the prevention of a commercially
important poultry disease.
The trial will test the efficacy of OxC-beta for the prevention
of morbidity and mortality resulting from the poultry pathogen
Clostridium perfringens. This bacterium causes intestinal damage in
chickens, leading to reduced feed conversion economics, clinical
illness and deaths. It is a troubling bacterial issue in worldwide
poultry production and a frequent reason for the prophylactic or
therapeutic use of antibiotics in feeds. This bacterium also causes
disease in humans; leading to "food poisoning" if ingested and "gas
gangrene" if introduced into wounds.
The trial is entitled "Preventative Effect of OxC-beta on
Necrotic Enteritis Model with Broiler Chickens." It will have five
study arms: testing two clinically and commercially relevant
dosages of OxC-beta against two commercial Antibiotic Growth
Promoters (AGPs) and a negative control group. The trial will first
reconfirm the optimal dose level of OxC-beta in this challenge
model and then conduct two parallel repeats of greater
statistical-significance.
The trial was designed by Professor Jang Hyung-Kwan, of the
College of Veterinary Medicine of Chonbuk National University of
Korea, Professor William Riley of Jinan University of Guangzhou,
China and Avivagen executives. The trial will be conducted by
Professor Jang at Chonbuk and the full protocol is targeted to
conclude in the first quarter of calendar 2015.
Cameron Groome, CEO and President, commented on Avivagen's
objectives for this trial "Professor Jang has developed an elegant
and efficient Clostridial challenge model, and we are pleased to be
working with him, Chonbuk and our Korean distributor on this study.
It is our hope that this study will provide results to support
national registrations for this poultry indication while also
emulating the result of a previous trial with OxC-beta against this
pathogen."
Cameron also discussed the various studies being established,
"Avivagen-sponsored OxC-beta studies are important as they may
provide publishable results in support of national product
registrations. This second Avivagen-sponsored trial is in addition
to trials designed and run by prospective commercial customers,
some of which are ongoing and others that are in the planning
stages. However, unlike Avivagen-sponsored trials, any positive
results of customer-sponsored OxC-beta trials might not be reported
other than by way of product sales."
About Avivagen Inc.
Avivagen Inc. is a publicly-listed life sciences company trading
on the TSX Venture Exchange under the ticker symbol "VIV". The
Company's goal is to develop and deliver scientifically-proven
solutions that can truly benefit companion and production animals
by employing natural mechanisms for maintaining good health.
Avivagen's targeted markets include Livestock Productivity and Pet
Wellness.
The company has sites located in partnership facilities of the
National Research Council of Canada (NRC) - in Ottawa, Ontario and
Charlottetown, Prince Edward Island. More information can be found
at www.avivagen.com.
About OxC-beta
Avivagen's proprietary and patent-protected technology is based
on its discoveries concerning carotenoid antioxidants. The novel
natural compounds discovered by Avivagen support the body's own
systems to maintain and enhance health, particularly by supporting
immune function. Avivagen's commercial-stage application of its
technology is Fully-Oxidized beta-Carotene (OxC-beta). OxC-beta
compounds occur naturally as carotenoid oxidation products in
vegetation, but in minute amounts. They have been developed to
support the health of companion animals and for use in the global
food animal market.
Research and study results indicate OxC-beta supports innate
immune function, which can help maintain good health. In pets,
OxC-beta supports overall vitality and energy, mobility and joint
function, skin, coat and gut. Results observed in food animals have
included healthier growth, better utilization of feed and decreased
mortality. In food animals, it is intended that use of OxC-beta
avoids the feeding of antibiotics.
The commercial products of Avivagen are OxC-beta for livestock,
Vivamune(TM) Health Chews and Oximunol(TM) Chewables.
About OxC-beta for Livestock
OxC-beta for Livestock is available as a 10% pre-mix sold in 1.0
or 5.0 Kg quantities for parts-per-million addition to animal
feeds, in accordance with producer-developed protocols. In past
studies, OxC-beta has been shown to support health and growth in
species such as fish, chicken, pigs and cattle. OxC-beta for
livestock is currently available for commercial sale in the Kingdom
of Thailand.
About Vivamune(TM) Health Chews - For dogs and
cats
Vivamune(TM) Health Chews, containing Avivagen's proprietary
active ingredients, are scientifically-formulated chews for dogs
and cats. Vivamune(TM) Health Chews work with a pet's own immune
system to maintain overall health and well-being. They are sold in
re-sealable packages of 30 chews and are currently available in the
United States by ordering on-line at www.vivamunehealth.com.
About Oximunol(TM) Chewables - For dogs
Oximunol(TM) Chewables are scientifically-formulated chewable
tablets that contain Avivagen's proprietary, patented active
ingredient OxC-beta. OxC-beta has been shown to stimulate innate
cellular immunity and may thereby help to maintain overall health
and well-being. Oximunol(TM) Chewables are distributed by Bayer
Healthcare LLC and are available through veterinarians for dogs of
all ages in the United States.
Forward Looking Statements
This document includes certain forward-looking statements
that are based upon current expectations, which involve risks and
uncertainties associated with the business of Avivagen Inc. and the
environment in which the business operates. Any statements
contained herein that are not statements of historical facts may be
deemed to be forward-looking, including those identified by the
expressions "will", "anticipate", "believe", "plan", "estimate",
"expect", "intend", and similar expressions. Statements relating to
expectations regarding access to new markets, new or increased
revenue streams, Avivagen's ability to secure additional clinical
trials and customer relationships and the results of such trials
and relationships and Avivagen's intention to identify suitable
technology license opportunities are all examples of
forward-looking statements. Forward-looking statements are subject
to a number of risks and uncertainties that could cause actual
results or events to differ materially from current expectations.
Avivagen's products may not gain market acceptance in new markets,
new or expected revenue streams may not materialise in the near
term or at all, Avivagen may not be able to secure clinical trials
or new customer relationships and the results of such trials and
relationships may not be favourable. Unless required by law,
Avivagen Inc. assumes no obligation to update the forward-looking
statements, or to update the reasons why actual results could
differ from those reflected in the forward-looking
statements.
For more information:
Avivagen Inc.
Cameron Groome
CEO & President
c.groome@avivagen.com
100 Sussex Drive
Ottawa, Ontario
Canada K1A 0R6
Head Office Phone: 613-949-8164
Website: www.avivagen.com
SOURCE: Avivagen Inc.
-----------------
|Copyright© 2014|
|Avivagen |
-----------------
Avivagen (TSXV:VIV)
Historical Stock Chart
From Jan 2025 to Feb 2025
Avivagen (TSXV:VIV)
Historical Stock Chart
From Feb 2024 to Feb 2025
